Patients with HR-positive, HER2-negative metastatic breast cancer should be consistently tested for ESR1 mutations to inform next lines of therapy.
Tajuana Bradley, MS, FNP-BC
Advertisement
Tajuana Bradley, MS, FNP-BC is a nurse practitioner at Northside Hospital Cancer Institute in Atlanta, Georgia
Articles by Tajuana Bradley, MS, FNP-BC
Advertisement
Latest Updated Articles
Consistent Monitoring for ESR1 Mutations Essential in HR+, HER2- mBCPublished: May 27th 2025 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Race Identified as Prognostic Indicator in Black Patients With AML
2
Families of Children With ALL Face Extreme Financial Toxicity
3
Fixed-Duration Venetoclax Regimens Yield Noninferior CLL PFS to Ibrutinib
4
FDA Approves Liso-Cel in Pretreated R/R Marginal Zone Lymphoma
5
